Improving kidney health in patients with chronic kidney disease through a systems biology approach.
Official title: A Systems Biology and Patient Stratification Approach to Improve Outcomes of Patients with Hypoxic Injury in Renal Tubular Cells in Chronic Kidney Diseases
Funded at University of Michigan at Ann Arbor · NIH-10755642 · Data updated 2026-11-12
This study is looking at how low oxygen levels affect kidney cells in people with chronic kidney disease, and it aims to create a helpful scoring system to better understand how these changes relate to patient outcomes, which could lead to improved treatments for those living with this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | April 1, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $169,560 |
| NIH project number | 5K08DK124449-05 |
| Project ID | NIH-10755642 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic kidney disease who exhibit signs of tubular injury.
✕Less likely to help
Patients with acute kidney injury or those without chronic kidney disease may not benefit from this research.
What this research studies
This research investigates how hypoxic injury affects renal tubular cells in patients with chronic kidney disease (CKD). By examining the role of Hypoxia Inducible Factor-1α (HIF-1α) and its impact on kidney tissue, the study aims to develop a scoring system that correlates HIF-1α activity with clinical outcomes. The approach includes identifying specific clinical and pathologic features that are associated with increased HIF-1α activity, which could lead to better patient stratification and targeted therapies. Ultimately, this research seeks to enhance understanding of CKD progression and improve treatment options for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for chronic kidney disease, potentially improving patient outcomes and quality of life.
How similar studies have gone: Previous research has shown promise in targeting the HIF-1α pathway for treating kidney-related conditions, indicating potential for success in this approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Schaub, Jennifer Ann — University of Michigan at Ann Arbor
- Study coordinator: Schaub, Jennifer Ann
Related research
Other NIH-funded projects on the same topics.
-
Chronic Kidney Disease of Unknown Cause in Agricultural Communities
A wide study to find what causes a serious kidney disease that affects workers in farming areas, by looking at people in high-risk regions.
-
Ubiquitin D as a potential target to help NASH, kidney disease, and liver cancer
A new approach targets a protein called UBD to help people with fatty liver disease, kidney disease, and liver cancer that can arise from liver disease.
-
Understanding Ubiquitin D for Liver and Kidney Diseases
This project looks at a protein called Ubiquitin D to find new ways to help people with liver conditions like NASH and HCC, and also chronic kidney disease.
-
Understanding CKDu in agricultural communities
This project brings researchers together to find the causes and clues behind chronic kidney disease of unknown cause in farming communities so people affected can get better prevention and care.
-
Investigating chronic kidney disease in agricultural communities
This study is looking into chronic kidney disease that affects farming communities, and it aims to find out what causes it and how it develops, so if you're a patient, your health information and samples could really help us learn more about this condition.
-
Metabolic Boost to Kidney Health in ADPKD
A Johns Hopkins-led study is exploring how fueling kidney cells with fats and FGF21 signals could slow kidney disease in adults with ADPKD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.